# Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

Source: https://onco.cc/trials/nct05952024/  
OnCo record `nct05952024` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Acalabrutinib, Rituximab in diffuse large b-cell lymphoma, run by AstraZeneca, now recruiting.

## Summary

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL is a phase 2 interventional study registered as NCT05952024 by AstraZeneca, with 80 participants planned, started 2024-07-16 and due to reach its primary completion in 2029-04-22. Interventions recorded: Acalabrutinib, Rituximab. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05952024
- Phase: 2
- Setting: A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)
- Sponsor: AstraZeneca
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT05952024: https://clinicaltrials.gov/study/NCT05952024

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05952024.json